149 related articles for article (PubMed ID: 34029474)
1. Aptamer-Based Logic Computing Reaction on Living Cells to Enable Non-Antibody Immune Checkpoint Blockade Therapy.
Yang Y; Xu J; Sun Y; Mo L; Liu B; Pan X; Liu Z; Tan W
J Am Chem Soc; 2021 Jun; 143(22):8391-8401. PubMed ID: 34029474
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Gao T; Mao Z; Li W; Pei R
J Mater Chem B; 2021 Jan; 9(3):746-756. PubMed ID: 33319876
[TBL] [Abstract][Full Text] [Related]
3. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
4. Cancer Cell-Selective PD-L1 Inhibition via a DNA Safety Catch to Enhance Immunotherapy Specificity.
Bi S; Chen W; Fang Y; Shen J; Zhang Q; Guo H; Ju H; Liu Y
Angew Chem Int Ed Engl; 2024 May; 63(20):e202402522. PubMed ID: 38421189
[TBL] [Abstract][Full Text] [Related]
5. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
6. Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy.
Chen G; Chen Z; Wen D; Wang Z; Li H; Zeng Y; Dotti G; Wirz RE; Gu Z
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3687-3692. PubMed ID: 32029590
[TBL] [Abstract][Full Text] [Related]
7. Click Reaction-Assisted Peptide Immune Checkpoint Blockade for Solid Tumor Treatment.
Xiao WY; Wang Y; An HW; Hou D; Mamuti M; Wang MD; Wang J; Xu W; Hu L; Wang H
ACS Appl Mater Interfaces; 2020 Sep; 12(36):40042-40051. PubMed ID: 32805827
[TBL] [Abstract][Full Text] [Related]
8. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
9. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-Gold Nanocage Composite for Photoactivated Immunotherapy.
Song W; Hu JJ; Song SJ; Xu Y; Yang H; Yang F; Zhou Y; Yu T; Qiu WX
ACS Appl Mater Interfaces; 2022 Sep; 14(38):42931-42939. PubMed ID: 36099584
[TBL] [Abstract][Full Text] [Related]
11. From mechanism to mouse: a tale of two bioorthogonal reactions.
Sletten EM; Bertozzi CR
Acc Chem Res; 2011 Sep; 44(9):666-76. PubMed ID: 21838330
[TBL] [Abstract][Full Text] [Related]
12. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
[TBL] [Abstract][Full Text] [Related]
13. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
[TBL] [Abstract][Full Text] [Related]
14. Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Xiong W; Qi L; Jiang N; Zhao Q; Chen L; Jiang X; Li Y; Zhou Z; Shen J
ACS Appl Mater Interfaces; 2021 Feb; 13(7):8026-8041. PubMed ID: 33577301
[TBL] [Abstract][Full Text] [Related]
15. Cell surface clicking of antibody-recruiting polymers to metabolically azide-labeled cancer cells.
Uvyn A; De Coen R; De Wever O; Deswarte K; Lambrecht BN; De Geest BG
Chem Commun (Camb); 2019 Sep; 55(73):10952-10955. PubMed ID: 31441915
[TBL] [Abstract][Full Text] [Related]
16. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action.
Surmiak E; Magiera-Mularz K; Musielak B; Muszak D; Kocik-Krol J; Kitel R; Plewka J; Holak TA; Skalniak L
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769226
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
19. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
20. Aptamer-Directed Protein-Specific Multiple Modifications of Membrane Glycoproteins on Living Cells.
Chen X; Qiu L; Cai R; Cui C; Li L; Jiang JH; Tan W
ACS Appl Mater Interfaces; 2020 Aug; 12(34):37845-37850. PubMed ID: 32706235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
